We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals
ATNM

31 hedge funds and large institutions have $8.16M invested in Actinium Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

59% more capital invested

Capital invested by funds: $5.14M → $8.16M (+$3.02M)

19% more funds holding

Funds holding: 26 → 31 (+5)

0.35% more ownership

Funds ownership: 0.24% → 0.59% (+0.35%)

Holders
31
Holders Change
+5
Holders Change %
+19.23%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
6
Reduced
3
Closed
5
Calls
$39K
Puts
–
Net Calls
+$39K
Net Calls Change
-$51K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$3.21M
2
SM
Sabby Management
Florida
+$1.78M
3
SCM
Sio Capital Management
New York
+$1.16M
4
AFM
Anson Funds Management
Texas
+$749K
5
CS
Credit Suisse
Switzerland
+$549K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$110K
2
DADC
D.A. Davidson & Co
Montana
-$58.5K
3
Group One Trading
Group One Trading
Illinois
-$22K
4
Renaissance Technologies
Renaissance Technologies
New York
-$14K
5
Creative Planning
Creative Planning
Kansas
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$2.52M +$3.21M +146,067 New
SM
2
Sabby Management
Florida
$1.4M +$1.78M +81,137 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.24M +$4.08K +186 +0.3%
SCM
4
Sio Capital Management
New York
$915K +$1.16M +53,009 New
AFM
5
Anson Funds Management
Texas
$589K +$749K +34,153 New
CS
6
Credit Suisse
Switzerland
$431K +$549K +25,000 New
BlackRock
7
BlackRock
New York
$358K +$14.1K +642 +3%
DCM
8
DAFNA Capital Management
California
$192K +$244K +11,100 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$109K – – –
BCM
10
Bridgeway Capital Management
Texas
$99K -$110K -5,000 -47%
Northern Trust
11
Northern Trust
Illinois
$61K – – –
Citadel Advisors
12
Citadel Advisors
Florida
$34K +$42.8K +1,952 New
Bank of New York Mellon
13
Bank of New York Mellon
New York
$28K – – –
DADC
14
D.A. Davidson & Co
Montana
$27K -$58.5K -2,667 -63%
VF
15
Virtu Financial
New York
$24K +$30.5K +1,392 New
California Public Employees Retirement System
16
California Public Employees Retirement System
California
$23K – – –
ARTA
17
A.R.T. Advisors
New York
$17K +$10.9K +496 +98%
Morgan Stanley
18
Morgan Stanley
New York
$15K +$22 +1 +0.1%
DY
19
Dowling & Yahnke
California
$13K – – –
RJFSA
20
Raymond James Financial Services Advisors
Florida
$10K – – –
SFG
21
SNS Financial Group
Minnesota
$10K +$4.39K +200 +50%
HFM
22
Hartford Financial Management
Connecticut
$10K +$8.05K +367 +158%
TSS
23
Two Sigma Securities
New York
$10K +$13K +592 New
Barclays
24
Barclays
United Kingdom
$9K – – –
State Street
25
State Street
Massachusetts
$7K – – –
1
2

ATNM Hedge Fund Activity: Q3 2017 in Review

31 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2017, worth a combined $8.16M — up 59% from $5.14M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ATNM positions and 5 closed out — a net gain of 6 holders — while 6 added to existing stakes and 3 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $3.21M. The largest seller was Bridgeway Capital Management, cutting an estimated $110K.

  • 31 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2017, up from 26 in Q2 2017.
  • Funds reported $8.16M of Actinium Pharmaceuticals stock for Q3 2017, up 59% quarter-over-quarter.
  • 11 funds opened new Actinium Pharmaceuticals positions in Q3 2017 and 5 closed out, a net change of +6 holders.
  • The largest Actinium Pharmaceuticals buyer in Q3 2017 was Armistice Capital, an estimated $3.21M added.
  • The largest Actinium Pharmaceuticals seller in Q3 2017 was Bridgeway Capital Management, an estimated $110K sold.

Based on aggregated 13F filings for Q3 2017.